MedEquity Capital

Founding partners W. Brandon Ingersoll and Jeffrey T. Ward lead investment decisions, supported by Principal Tom Beausejour and Vice President Leland Garrahan. Ingersoll and Ward each have over 25 years of healthcare experience and have held CEO or Chairman roles at multiple portfolio companies. Beausejour joined in 2016 from Vertex Pharmaceuticals, while Garrahan joined after consulting roles at L.E.K. and Accenture (per the firm).

MedEquity states that many of its prospects are privately owned businesses seeking a transaction on a direct basis or outside a formal auction process. The firm credits long-term relationships with industry executives and financial institutions for access to these opportunities. The two founders have operated in healthcare for more than two decades, giving them direct reach into the lower middle market where personal networks dominate deal origination.

The firm targets buyout and growth capital investments in established, profitable companies with strong cash flow. For platform investments, MedEquity seeks companies with at least $5 million in revenue and $1 million to $10 million in EBITDA. Tuck-in acquisitions have no revenue or EBITDA minimum. The firm also selectively considers recapitalizations that provide full or partial liquidity to owners.

MedEquity states it will rarely invest in a specific technology, product, or compound, preferring healthcare service or distribution businesses that can capitalize on broad technology trends without taking obsolescence risk. The firm does not back early-stage life sciences companies or businesses with significant regulatory approval dependencies, focusing instead on cash-flowing service providers and specialty pharmacies.

MedEquity does not publicly disclose its limited partner base. The firm was founded by Ingersoll and Ward, who self-describe as having generated returns for company founders and investors that exceed peer benchmarks (per the firm). Without a disclosed wealth-origin event or institutional LP roster, the exact composition of its capital base remains private.